Nicholas Andrew Turner MD MHSc
Assistant Professor - Division of Infectious Diseases, Associate TB Controller/TB Physician
Join to view full profile
40 Medicine CircleClinic 1KDurham, NC 27710
Phone+1 919-681-6261
Dr. Turner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nicholas Turner is an infectious disease specialist based in Durham, NC. He completed his medical education and training at Duke University, including a fellowship in infectious disease and a residency in internal medicine/pediatrics. Dr. Turner currently serves as a physician at Wake County Public Health and Southern Regional AHEC Family Medicine Center, as well as an assistant professor at Duke University Hospital. His expertise encompasses conditions like infective endocarditis, tuberculosis, Clostridium difficile colitis, HIV/AIDS, and mycobacterial infections. Dr. Turner has contributed to multiple publications in notable journals such as Infection Control and Hospital Epidemiology and JAMA. He is also involved in clinical trials focusing on the treatment of Staphylococcus aureus bacteremia and penicillin allergy management.
Education & Training
Duke UniversityMHSc, Clinical Research Training Program, 2017 - 2019
Duke University HospitalFellowship, Infectious Disease, 2016 - 2019- Duke University HospitalResidency, Internal Medicine/Pediatrics, 2012 - 2016
Duke University School of MedicineClass of 2012
Certifications & Licensure
NC State Medical License 2012 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
American Board of Pediatrics Pediatrics
Clinical Trials
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Start of enrollment: 2021 Apr 22
- The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge Start of enrollment: 2021 Jul 01
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Start of enrollment: 2018 Aug 26
Publications & Presentations
PubMed
- Upsetting the Hierarchy: Time to Update Clinical Trial Outcomes?Nicholas A Turner, Sarah B Doernberg
Clinical Microbiology and Infection. 2026-11-04 - Cefepime-Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-β-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, M...Rajiv Karthik Krishnaswami, Dilip Kumar Dubey, Rahul Vasantrao Sonawane, Prashant Raghunath Potdar, Deepak Kumar
Clinical Infectious Diseases. 2026-10-23 - Reexamining Novel Risk Factors for Community-Acquired: A Multimodal Approach.Nicholas A Turner, Angela Harris, Benjamin J Clark, Bobby G Warren, Aaron Barrett
Open Forum Infectious Diseases. 2026-10-01
Press Mentions
Trial Shows Promise for New Bloodborne Staph Infection TreatmentAugust 14th, 2025- Study: Dalbavancin Similar to Standard Treatment for Staph BacteremiaAugust 14th, 2025
- Two-Dose Antibiotic Offers New Hope for Treating Deadly Staph InfectionsAugust 13th, 2025
Grant Support
- Role of C difficile Colonization in Risk of DiseaseDUKE UNIVERSITY2025–2030
Research History
- Antibiotic Resistance Leadership Group - Research Fellow2017 - 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: